Pharma company FDC Limited reported a steady performance for the quarter ended June 30, 2025 (Q1 FY26), with consolidated net profit rising 2% year-on-year to ₹121.3 crore compared to ₹119 crore in the same quarter last year.
Revenue from operations rose marginally by 1.6% to ₹648.4 crore, up from ₹638.3 crore in Q1 FY25. Total income stood at ₹683.9 crore, aided by ₹35.5 crore in other income for the quarter.
However, the company saw a dip in operational profitability. EBITDA fell 4% year-on-year to ₹141 crore from ₹146.6 crore in the previous year. Correspondingly, EBITDA margin contracted slightly to 22% from 23% YoY.
Total expenses increased to ₹524.1 crore from ₹503.9 crore in Q1 FY25, primarily driven by higher material costs and employee expenses. The company maintained a stable financial performance despite sector-wide pricing pressures.
Profit before tax came in at ₹159.8 crore, compared to ₹162.7 crore a year ago. Tax expenses rose to ₹37.3 crore, resulting in a marginal YoY increase in net profit.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
